B-cell-directed therapy for inflammatory skin diseases

Journal of Investigative Dermatology

Volumn 129, Issue 2, 2009, Pages 289-301

  Nagel, Angela ^a   Hertl, Michael ^a   Eming, Rüdiger ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 623; ANTINUCLEAR ANTIBODY; ATACICEPT; BELIMUMAB; CD20 ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPRATUZUMAB; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ALPHA; MONOCLONAL ANTIBODY; OCRELIZUMAB; RITUXIMAB; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; B LYMPHOCYTE; CHILL; CLINICAL TRIAL; CYTOTOXICITY; DERMATOMYOSITIS; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HEADACHE; HUMAN; HYPOTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; NONHUMAN; OPPORTUNISTIC INFECTION; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; RHEUMATOID ARTHRITIS; SKIN INFLAMMATION; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TREATMENT RESPONSE; URTICARIA;

EID: 58449097564     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2008.192     Document Type: Note

References (156)

1. Ahmadi-Simab K, Lamprecht P, Nolle B, Ai M, Gross WL (2005) Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab. Ann Rheum Dis 64:1087-8
2. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR (2006) Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 355:1772-9
3. Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ et al. (2004) Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 50:3580-90
4. Aries PM, Hellmich B, Voswinkel J, Both M, Nolle B, Holl-Ulrich K et al. (2006) Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 65:853-8
5. Arin MJ, Engert A, Krieg T, Hunzelmann N (2005) Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol 153:620-5
6. Arkfeld DG (2008) The potential utility of B cell-directed biologic therapy in autoimmune diseases. Rheumatol Int 28:205-15
7. Asashima N, Fujimoto M, Watanabe R, Nakashima H, Yazawa N, Okochi H et al. (2006) Serum levels of BAFF are increased in bullous pemphigoid but not in pemphigus vulgaris. Br J Dermatol 155:330-6
8. Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG et al. (2003) Generation and characterization of Lympho-Stat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 48:3253-65
9. Berger JR (2007) Progressive multifocal leukoencephalopathy. Curr Neurol Neurosci Rep 7:461-9
10. Binstadt BA, Geha RS, Bonilla FA (2003) IgG Fc receptor polymorphisms in human disease: implications for intravenous immunoglobulin therapy. J Allergy Clin Immunol 111:697-703
11. Bombardieri M, Barone F, Humby F, Kelly S, McGurk M, Morgan P et al. (2007) Activation-induced cytidine deaminase expression in follicular dendritic cell networks and interfollicular large B cells supports functionality of ectopic lymphoid neogenesis in autoimmune sialoadenitis and MALT lymphoma in Sjogren's syndrome. J Immunol 179:4929-38
12. Bonnekoh B, Schulz M, Franke I, Gollnick H (2002) Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab. J Cancer Res Clin Oncol 128:161-6
13. Borradori L, Lombardi T, Samson J, Girardet C, Saurat JH, Hugli A (2001) Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus. Arch Dermatol 137: 269-72
14. Bouaziz JD, Yanaba K, Venturi GM, Wang Y, Tisch RM, Poe JC et al. (2007) Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. Proc Natl Acad Sci USA 104:20878-83
15. Brink R (2006) Regulation of B cell self-tolerance by BAFF. Semin Immunol 18:276-83
16. Browning JL (2006) B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov 5:564-76
17. Cambridge G, Leandro MJ, Edwards JC, Ehrenstein MR, Salden M, Bodman-Smith M et al. (2003) Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 48:2146-54
18. Cambridge G, Leandro MJ, Teodorescu M, Manson J, Rahman A, Isenberg DA et al. (2006) B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 54:3612-22
19. Canete JD, Santiago B, Cantaert T, Sanmarti R, Palacin A, Celis R et al. (2007) Ectopic lymphoid neogenesis in psoriatic arthritis. Ann Rheum Dis 66:720-6
20. Carnahan J, Stein R, Qu Z, Hess K, Cesano A, Hansen HJ et al. (2007) Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol 44:1331-41
21. Carnahan J, Wang P, Kendall R, Chen C, Hu S, Boone T et al. (2003) Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res 9:3982S-90S
22. Carr DR, Heffernan MP (2007) Off-label uses of rituximab in dermatology. Dermatol Ther 20:277-87
23. Chang SK, Arendt BK, Darce JR, Wu X, Jelinek DF (2006) A role for BLyS in the activation of innate immune cells. Blood 108:2687-94
24. Chatham W, Stohl W, Petri M, Furie R, Merrill JT, Wallace DJ et al. (2008) Progressive Normalization of Autoantibody, Immunoglobulin, and Complement Levels over 2.5 Years of Belimumab (Anti-BLyS Monoclonal Antibody) Therapy in SLE Patients. IMMUNO2008 Scientific Meeting, February 14-17, Berlin, Germany
25. Cheema GS, Roschke V, Hilbert DM, Stohl W (2001) Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 44:1313-9
26. Chung L, Genovese MC, Fiorentino DF (2007) A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 143:763-7
27. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC et al. (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54:2793-806
28. Cooper HL, Healy E, Theaker JM, Friedmann PS (2003) Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (rituximab). Clin Exp Dermatol 28:366-8
29. Cooper MA, Willingham DL, Brown DE, French AR, Shih FF, White AJ (2007) Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum 56:3107-11
30. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ (2005) The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 8:140-74
31. Crichlow SM, Mortimer NJ, Harman KE (2007) A successful therapeutic trial of rituximab in the treatment of a patient with recalcitrant, high-titre epidermolysis bullosa acquisita. Br J Dermatol 156:194-6
32. Dall'era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A et al. (2007) Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicenter, phase ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 56:4142-50
33. Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK (1996) Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 97:2063-73
34. Devauchelle-Pensec V, Pennec Y, Morvan J, Pers JO, Daridon C, Jousse-Joulin S et al. (2007) Improvement of Sjogren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 57:310-7
35. Dinh HV, McCormack C, Hall S, Prince HM (2007) Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. J Am Acad Dermatol 56:148-53
36. Dorner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR (2006) Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 8:R74
37. Dorner T, Lipsky PE (2007) B-cell targeting: a novel approach to immune intervention today and tomorrow. Expert Opin Biol Ther 7:1287-99
38. Dupuy A, Viguier M, Bedane C, Cordoliani F, Blaise S, Aucouturier F et al. (2004) Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol 140:91-6
39. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR et al. (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572-81
40. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A et al. (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54:1390-400
41. Eming R, Hertl M (2006) Immunoadsorption in pemphigus. Autoimmunity 39:609-16
42. Eming R, Rech J, Barth S, Kalden JR, Schuler G, Harrer T et al. (2006) Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption. Dermatology 212:177-87
43. Eming R, Nagel A, Wolff-Franke S, Podstawa E, Debus D, Hertl M (2008) Rituximab exerts a dual effect in pemphigus vulgaris. J Invest Dermatol 19 June [E-pub ahead of print]
44. Engel P, Wagner N, Miller AS, Tedder TF (1995) Identification of the ligand-binding domains of CD22, a member of the immunoglobulin superfamily that uniquely binds a sialic acid-dependent ligand. J Exp Med 181:1581-6
45. Eriksson P (2005) Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 257:540-8
46. Espana A, Fernandez-Galar M, Lloret P, Sanchez-Ibarrola A, Panizo C (2004) Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations. J Am Acad Dermatol 50:974-6
47. Fanale MA, Younes A (2007) Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Drugs 67:333-50
48. Ferraro AJ, Day CJ, Drayson MT, Savage CO (2005) Effective therapeutic use of rituximab in refractory Wegener's granulomatosis. Nephrol Dial Transplant 20:622-5
49. Ferraro AJ, Drayson MT, Savage CO, MacLennan IC (2008) Levels of autoantibodies, unlike antibodies to all extrinsic antigen groups, fall following B cell depletion with rituximab. Eur J Immunol 38:292-8
50. Fink-Puches R, Wolf IH, Zalaudek I, Kerl H, Cerroni L (2005) Treatment of primary cutaneous B-cell lymphoma with rituximab. J Am Acad Dermatol 52:847-53
51. Genovese MC, Kaine JL, Kohen MD, Lowenstein MB, Del Guidice J, Baldassare AR et al. (2006) Safety and clinical activity of ocrelizumab (a humanized antibody targeting CD20+ B cells) in combination with methotrexate (MTX) in moderate-severe rheumatoid arthritis (RA) patients (pts) (PhI/II ACTION study). Arthritis Rheum 54:S66-7
52. Goebeler M, Herzog S, Brocker EB, Zillikens D (2003) Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab. Br J Dermatol 149:899-901
53. Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, Diehl L et al. (2005) Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 174:817-26
54. Halpern WG, Lappin P, Zanardi T, Cai W, Corcoran M, Zhong J et al. (2006) Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects. Toxicol Sci 91:586-99
55. Hamaguchi Y, Uchida J, Cain DW, Venturi GM, Poe JC, Haas KM et al. (2005) The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J Immunol 174:4389-99
56. Heinzerling L, Dummer R, Kempf W, Schmid MH, Burg G (2000a) Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma. Arch Dermatol 136:374-8
57. Heinzerling LM, Urbanek M, Funk JO, Peker S, Bleck O, Neuber K et al. (2000b) Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. Cancer 89:1835-44
58. Heizmann M, Itin P, Wernli M, Borradori L, Bargetzi MJ (2001) Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol 66:142-4
59. Herrmann G, Hunzelmann N, Engert A (2003) Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Br J Dermatol 148:602-3
60. Hertl M, Eming R, Veldman C (2006) T cell control in autoimmune bullous skin disorders. J Clin Invest 116:1159-66
61. Hertl M, Zillikens D, Borradori L, Bruckner-Tuderman L, Burckhard H, Eming R et al. (2008) Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges 6:366-73
62. Hilario-Vargas J, Dasher DA, Li N, Aoki V, Hans-Filho G, dos Santos V et al. (2006) Prevalence of anti-desmoglein-3 antibodies in endemic regions of Fogo selvagem in Brazil. J Invest Dermatol 126:2044-8
63. Hoque SR, Black MM, Cliff S (2007) Paraneoplastic pemphigus associated with CD20-positive follicular non-Hodgkin's lymphoma treated with rituximab: a third case resistant to rituximab therapy. Clin Exp Dermatol 32:172-5
64. Huard B, Schneider P, Mauri D, Tschopp J, French LE (2001) T cell costimulation by the TNF ligand BAFF. J Immunol 167:6225-31
65. Jacob CO, Pricop L, Putterman C, Koss MN, Liu Y, Kollaros M et al. (2006) Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF. J Immunol 177:2671-80
66. Jacobi AM, Goldenberg DM, Hiepe FT, Radbruch A, Burmester GR, Dorner T (2008) Differential effects of epratuzumab on peripheral blood B cells of SLE patients versus normal controls. Ann Rheum Dis 67:450-7
67. Joly P, Mouquet H, Roujeau JC, D'Incan M, Gilbert D, Jacquot S et al. (2007) A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 357:545-52
68. Jonsdottir T, Gunnarsson I, Risselada A, Welin Henriksson E, Klareskog L, van Vollenhoven RF (2008) Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis 67:330-4
69. Jonsson MV, Szodoray P, Jellestad S, Jonsson R, Skarstein K (2005) Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjogren's syndrome. J Clin Immunol 25:189-201
70. Kallel Sellami M, Ben Ayed M, Mouquet H, Drouot L, Zitouni M, Mokni M et al. (2004) Anti-desmoglein 1 antibodies in Tunisian healthy subjects: arguments for the role of environmental factors in the occurrence of Tunisian pemphigus foliaceus. Clin Exp Immunol 137:195-200
71. Kallenbach M, Duan H, Ring T (2005) Rituximab induced remission in a patient with Wegener's granulomatosis. Nephron Clin Pract 99:c92-6
72. Kaushik VV, Reddy HV, Bucknall RC (2006) Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndrome. Ann Rheum Dis 65:1116-7
73. Kawasaki H, Tsunoda K, Hata T, Ishii K, Yamada T, Amagai M (2006) Synergistic pathogenic effects of combined mouse monoclonal anti-desmoglein 3 IgG antibodies on pemphigus vulgaris blister formation. J Invest Dermatol 126:2621-30
74. Keogh KA, Wylam ME, Stone JH, Specks U (2005) Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52:262-8
75. Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U (2006) Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 173:180-7
76. Kerl K, Prins C, Saurat JH, French LE (2006) Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases. Br J Dermatol 155:1197-200
77. Kong HH, Prose NS, Ware RE, Hall RP III (2005) Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab). Pediatr Dermatol 22:461-4
78. Koukoulaki M, Smith KG, Jayne DR (2006) Rituximab in Churg-Strauss syndrome. Ann Rheum Dis 65:557-9
79. Lacouture ME, Baron JM, Jani AB, Laumann AE, Soltani K (2005) Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibody. Clin Exp Dermatol 30:46-8
80. Le Pottier L, Bendaoud B, Dueymes M, Daridon C, Youinou P, Shoenfeld Y et al. (2007) BAFF, a new target for intravenous immunoglobulin in autoimmunity and cancer. J Clin Immunol 27:257-65
81. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC (2006) Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 54:613-20
82. Levine TD (2005) Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 52:601-7
83. Li N, Zhao M, Hilario-Vargas J, Prisayanh P, Warren S, Diaz LA et al. (2005) Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest 115:3440-50
84. Lin MS, Swartz SJ, Lopez A, Ding X, Fernandez-Vina MA, Stastny P et al. (1997) Development and characterization of desmoglein-3 specific T cells from patients with pemphigus vulgaris. J Clin Invest 99:31-40
85. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ et al. (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50:2580-9
86. Mackay F, Schneider P, Rennert P, Browning J (2003) BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 21:231-64
87. Mackay F, Silveira PA, Brink R (2007) B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling. Curr Opin Immunol 19:327-36
88. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P et al. (1999) Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 190:1697-710
89. Marks SD, Patey S, Brogan PA, Hasson N, Pilkington C, Woo P et al. (2005) B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 52:3168-74
90. Martin F, Chan AC (2004) Pathogenic roles of B cells in human autoimmunity; insights from the clinic. Immunity 20:517-27
91. Mason D (1996) The role of B cells in the programming of T cells for IL-4 synthesis. J Exp Med 183:717-9
92. Matsushita T, Fujimoto M, Hasegawa M, Matsushita Y, Komura K, Ogawa F et al. (2007a) BAFF antagonist attenuates the development of skin fibrosis in tight-skin mice. J Invest Dermatol 127:2772-80
93. Matsushita T, Hasegawa M, Matsushita Y, Echigo T, Wayaku T, Horikawa M et al. (2007b) Elevated serum BAFF levels in patients with localized scleroderma in contrast to other organ-specific autoimmune diseases. Exp Dermatol 16:87-93
94. Matsushita T, Hasegawa M, Yanaba K, Kodera M, Takehara K, Sato S (2006) Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 54:192-201
95. Morrison LH (2004) Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab). J Am Acad Dermatol 51:817-9
96. Munafo A, Priestley A, Nestorov I, Visich J, Rogge M (2007) Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers. Eur J Clin Pharmacol 63:647-56
97. Nagasaki A, Matsue H, Kawamura T, Kanzaki M, Inozume T, Nakamura Y et al. (2006) Complete remission of a primary cutaneous follicle-center cell lymphoma (EORTC criteria)/diffuse large B-cell lymphoma (WHO criteria) by single first-line therapy with rituximab. J Dermatol 33:377-9
98. Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA (2007) B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis 66:1259-62
99. Niedermeier A, Eming R, Pfutze M, Neumann CR, Happel C, Reich K et al. (2007) Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies). Arch Dermatol 143:192-8
100. Niedermeier A, Worl P, Barth S, Schuler G, Hertl M (2006) Delayed response of oral pemphigus vulgaris to rituximab treatment. Eur J Dermatol 16:266-70
101. O'Keefe TL, Williams GT, Batista FD, Neuberger MS (1999) Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies. J Exp Med 189:1307-13
102. Paul T, Radny P, Krober SM, Paul A, Blaheta HJ, Garbe C (2001) Intralesional rituximab for cutaneous B-cell lymphoma. Br J Dermatol 144:1239-43
103. Pers JO, Daridon C, Devauchelle V, Jousse S, Saraux A, Jamin C et al. (2005) BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 1050:34-9
104. Pers JO, Devauchelle V, Daridon C, Bendaoud B, Le Berre R, Bordron A et al. (2007) BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjogren's syndrome. Arthritis Rheum 56:1464-77
105. Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K et al. (2005) Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum 52:2740-50
106. Prasad NK, Papoff G, Zeuner A, Bonnin E, Kazatchkine MD, Ruberti G et al. (1998) Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 161:3781-90
107. Ramanujam M, Wang X, Huang W, Liu Z, Schiffer L, Tao H et al. (2006) Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest 116:724-34
108. Roguedas AM, Watier H, Paintaud G, de Muret A, Vaillant L, Machet L (2005) Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma. Br J Dermatol 152:541-4
109. Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP (2006) Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 54:2377-86
110. Sakkas LI, Chikanza IC, Platsoucas CD (2006) Mechanisms of disease: the role of immune cells in the pathogenesis of systemic sclerosis. Nat Clin Pract Rheumatol 2:679-85
111. Salopek TG, Logsetty S, Tredget EE (2002) Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol 47:785-8
112. Schaller M, Stohl W, Tan SM, Benoit VM, Hilbert DM, Ditzel HJ (2005) Raised levels of anti-glucose-6-phosphate isomerase IgG in serum and synovial fluid from patients with inflammatory arthritis. Ann Rheum Dis 64:743-9
113. Schmidt E, Benoit S, Brocker EB, Zillikens D, Goebeler M (2006) Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab. Arch Dermatol 142:147-50
114. Schmidt E, Herzog S, Brocker EB, Zillikens D, Goebeler M (2005) Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab. Br J Dermatol 153:449-51
115. Schmidt E, Seitz CS, Benoit S, Brocker EB, Goebeler M (2007) Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol 156:352-6
116. Schneider P (2005) The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol 17:282-9
117. Seror R, Sordet C, Guillevin L, Hachulla E, Masson C, Ittah M et al. (2007) Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann Rheum Dis 66:351-7
118. Seyler TM, Park YW, Takemura S, Bram RJ, Kurtin PJ, Goronzy JJ et al. (2005) BLyS and APRIL in rheumatoid arthritis. J Clin Invest 115:3083-92
119. Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A et al. (2005a) Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 52:501-13
120. Sfikakis PP, Boletis JN, Tsokos GC (2005b) Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol 17:550-7
121. Sfikakis PP, Souliotis VL, Fragiadaki KG, Moutsopoulos HM, Boletis JN, Theofilopoulos AN (2007) Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol 123:66-73
122. Shimanovich I, Herzog S, Schmidt E, Opitz A, Klinker E, Brocker EB et al. (2006) Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption. Clin Exp Dermatol 31:768-74
123. Shimanovich I, Nitschke M, Rose C, Grabbe J, Zillikens D (2008) Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins. Br J Dermatol 158:382-8
124. Simon D, Hosli S, Kostylina G, Yawalkar N, Simon HU (2008) Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 121:122-8
125. Smith KG, Jones RB, Burns SM, Jayne DR (2006) Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 54:2970-82
126. Stasi R, Cooper N, Del Poeta G, Stipa E, Evangelista ML, Abruzzese E et al. (2008) Analysis of regulatory T cell changes in patients with idiopathic thrombocytopenic purpura receiving B-cell depleting therapy with rituximab. Blood 112:1147-50
127. Steinfeld SD, Tant L, Burmester GR, Teoh NK, Wegener WA, Goldenberg DM et al. (2006) Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren's syndrome: an open-label phase I/II study. Arthritis Res Ther 8:R129
128. Stohl W, Looney RJ (2006) B cell depletion therapy in systemic rheumatic diseases: different strokes for different folks? Clin Immunol 121:1-12
129. Stohl W, Wallace DJ, Merrill JT, Chatham W, Gruhn W, Aranow C et al. (2006) Changes in circulating B-cell counts, autoantibody levels and immunoglobulins that associate with therapeutic responsiveness in SLE to BLyS protein antagonism by belimumab. Arthritis Rheum 54:S780
130. Tahir H, Rohrer J, Bhatia A, Wegener WA, Isenberg DA (2005) Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab. Rheumatology) 44:561-2
131. Tanaka Y, Yamamoto K, Takeuchi T, Nishimoto N, Miyasaka N, Sumida T et al. (2007) A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol 17:191-7
132. Tangye SG, Bryant VL, Cuss AK, Good KL (2006) BAFF, APRIL and human B cell disorders. Semin Immunol 18:305-17
133. Tedder TF, Poe JC, Haas KM (2005) CD22: A Multifunctional Receptor That Regulates B Lymphocyte Survival and Signal Transduction. Adv Immunol 88:1-50
134. Thien M, Phan TG, Gardam S, Amesbury M, Basten A, Mackay F et al. (2004) Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20:785-98
135. Thurlings RM, Vos K, Wijbrandts CA, Zwinderman A, Gerlag DM, Tak PP (2008) Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis 67:917-25
136. Timmer TC, Baltus B, Vondenhoff M, Huizinga TW, Tak PP, Verweij CL et al. (2007) Inflammation and ectopic lymphoid structures in rheumatoid arthritis synovial tissues dissected by genomics technology: identification of the interleukin-7 signaling pathway in tissues with lymphoid neogenesis. Arthritis Rheum 56:2492-502
137. Tokunaga M, Fujii K, Saito K, Nakayamada S, Tsujimura S, Nawata M et al. (2005) Downregulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology 44:176-82
138. Tokunaga M, Saito K, Kawabata D, Imura Y, Fujii T, Nakayamada S et al. (2007) Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 66:470-5
139. Toubi E, Kessel A, Slobodin G, Boulman N, Pavlotzky E, Zisman D et al. (2007) Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 66:818-20
140. Tsunoda K, Ota T, Suzuki H, Ohyama M, Nagai T, Nishikawa T et al. (2002) Pathogenic autoantibody production requires loss of tolerance against desmoglein 3 in both T and B cells in experimental pemphigus vulgaris. Eur J Immunol 32:627-33
141. Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM et al. (2004) The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 199:1659-69
142. Vallerskog T, Gunnarsson I, Widhe M, Risselada A, Klareskog L, van Vollenhoven R et al. (2007) Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol 122:62-74
143. Vallerskog T, Heimburger M, Gunnarsson I, Zhou W, Wahren-Herlenius M, Trollmo C et al. (2006) Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 8:R167
144. Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O, Portales-Perez D, Baranda L, Abud-Mendoza C et al. (2006) Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 8:R83
145. Visentini M, Granata M, Veneziano ML, Borghese F, Carlesimo M, Pimpinelli F et al. (2007) Efficacy of low-dose rituximab for mixed cryoglobulinemia. Clin Immunol 125:30-3
146. Vos K, Thurlings RM, Wijbrandts CA, van Schaardenburg D, Gerlag DM, Tak PP (2007) Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum 56:772-8
147. Vugmeyster Y, Beyer J, Howell K, Combs D, Fielder P, Yang J et al. (2005) Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis. J Immunother 28:212-9
148. Wallace D, Merrill JT, Stohl W, Furie R, Ginzler EM, Petri M et al. (2008) Long-term Safety Profile of Belimumab (Fully Human Monoclonal Antibody to BLyS) in Patients with Systemic Lupus Erythematosus (SLE). IMMUNO2008 Scientific Meeting, February 14-17, Berlin, Germany
149. Walsh M, Jayne D (2007) Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future. Kidney Int 72:676-82
150. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC (2003) Predominant autoantibody production by early human B cell precursors. Science 301:1374-7
151. Willems M, Haddad E, Niaudet P, Kone-Paut I, Bensman A, Cochat P et al. (2006) Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr 148:623-7
152. Wucherpfennig KW, Yu B, Bhol K, Monos DS, Argyris E, Karr RW et al. (1995) Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity: charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris. Proc Natl Acad Sci USA 92:11935-9
153. Ye Q, Wang L, Wells AD, Tao R, Han R, Davidson A et al. (2004) BAFF binding to T cell-expressed BAFF-R costimulates T cell proliferation and alloresponses. Eur J Immunol 34:2750-9
154. Yurasov S, Wardemann H, Hammersen J, Tsuiji M, Meffre E, Pascual V et al. (2005) Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med 201:703-11
155. Zaja F, De Vita S, Mazzaro C, Sacco S, Damiani D, De Marchi G et al. (2003) Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101:3827-34
156. Zhang J, Roschke V, Baker KP, Wang Z, Alarcon GS, Fessler BJ et al. (2001) Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 166:6-10